Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2013

Open Access 01-11-2013 | Original Article

Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study

Published in: Supportive Care in Cancer | Issue 11/2013

Login to get access

Abstract

Background

The PERFORM Questionnaire is a 12-item scale developed for assessing fatigue in cancer patients in the clinical practice. It has advantages over other tools in that it is short and includes beliefs and attitudes of patients about fatigue. It was psychometrically validated in cancer patients with and without anemia.

Purpose

We evaluated the usefulness of the PERFORM scale to measure fatigue in a large study focusing exclusively on anemic patients.

Methods

This was an observational, multicenter, prospective, 3-month study in cancer patients with hemoglobin (Hb)≤11 g/dl. Fatigue was assessed using the PERFORM questionnaire. The overall score ranges from 12 (no fatigue) to 60 (maximum fatigue).

Results

We included 667 patients: 54.1 % women, mean age 60 (standard deviation, 12) years. A highly significant, but mild correlation was observed between low baseline Hb and high patient perception of fatigue (r with PERFORM score=−0.215, p < 0.0001). Of the patients, 65.8 % improved Hb level during follow-up (increase of ≥1 g/dL and/or achieving >11 g/dL), which translated into a significant improvement in the PERFORM score [mean (95 % confidence interval (CI)] change, −1.2 (−0.04 to −2.4), whereas more fatigue was observed in patients without improvement in Hb [change (95 % CI) in PERFORM, +3.3 (1.5 to 5)]. In a multivariate linear regression analysis, the independent factors associated to fatigue at 3 months were a low Hb level, a low Karnofsky index, active chemotherapy, cancer treatment with palliative intention, and transfusion need in the last 3 months.

Conclusions

Minimal increases or decreases in Hb of ≥1 g/dL were associated with meaningful changes in patient-perceived fatigue as measured with the PERFORM questionnaire. In addition to anemia severity, other factors such as active chemotherapy and advanced disease contribute to perception of fatigue by cancer patients.
Appendix
Available only for authorised users
Literature
1.
Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C (2000) NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14:151–161
2.
Diaz N, Menjon S, Rolfo C, Garcia-Alonso P, Carulla J, Magro A, Miramon J, Rodriguez CA, de Castellar R, Gasquet JA (2008) Patients’ perception of cancer-related fatigue: results of a survey to assess the impact on their everyday life. Clin Transl Oncol 10:753–757PubMedCrossRef
3.
Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M (2011) I’m so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 19:1419–1427CrossRef
4.
Sprangers MA, Van Dam FS, Broersen J, Lodder L, Wever L, Visser MR, Oosterveld P, Smets EM (1999) Revealing response shift in longitudinal research on fatigue: the use of the thentest approach. Acta Oncol 38:709–718PubMedCrossRef
5.
Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manag 18:233–242CrossRef
6.
Molassiotis A, Morris PJ (1999) Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation. Cancer Nurs 22:340–349PubMedCrossRef
7.
Berger AM, Farr L (1999) The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum 26(10):1663–1671PubMed
8.
Romito F, Montanaro R, Corvasce C, Di Bisceglie M, Mattioli V (2008) Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients? Support Care Cancer 16:943–946PubMedCrossRef
9.
Yennurajalingam S, Palmer JL, Zhang T, Poulter V, Bruera E (2008) Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer 16:1125–1130PubMedCrossRef
10.
11.
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875–2882PubMed
12.
Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J (2003) Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 39:335–345PubMedCrossRef
13.
Carteni G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P (2007) Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Support Care Cancer 15:1057–1066PubMedCrossRef
14.
Gerber LH, Stout N, McGarvey C, Soballe P, Shieh CY, Diao G, Springer BA, Pfalzer LA (2011) Factors predicting clinically significant fatigue in women following treatment for primary breast cancer. Support Care Cancer 19:1581–1591PubMedCrossRef
15.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306PubMedCrossRef
16.
Canaparo R, Casale F, Muntoni E, Zara GP, Della Pepa C, Berno E, Pons N, Fornari G, Eandi M (2000) Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 50:146–153PubMedCrossRef
17.
Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25:371–379PubMedCrossRef
18.
Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59:1–11PubMedCrossRef
19.
Demetri GD (2001) Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84(Suppl 1):31–37PubMedCrossRef
20.
21.
Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR (2006) Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12:2759–2766PubMedCrossRef
22.
Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW (2003) T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst 95:1165–1168PubMedCrossRef
23.
Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, Asgharzadeh F, Roth S, Budach W, Franz M, Willers R (2007) Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 25:3313–3320PubMedCrossRef
24.
Bower JE, Ganz PA, Aziz N (2005) Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 67:277–280PubMedCrossRef
25.
Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW (2007) Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun 21:251–258PubMedCrossRef
26.
Ancoli-Israel S, Moore PJ, Jones V (2001) The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 10:245–255CrossRef
27.
Berger AM, Farr LA, Kuhn BR, Fischer P, Agrawal S (2007) Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manag 33:398–409CrossRef
28.
Roscoe JA, Kaufman ME, Matteson-Rusby SE, Palesh OG, Ryan JL, Kohli S, Perlis ML, Morrow GR (2007) Cancer-related fatigue and sleep disorders. Oncologist 12(Suppl 1):35–42PubMedCrossRef
29.
Baro E, Carulla J, Cassinello J, Colomer R, Mata JG, Gascon P, Gasquet JA, Rodriguez CA, Valentin V (2011) Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. Support Care Cancer 19:657–666PubMedCrossRef
30.
Baro E, Carulla J, Cassinello J, Colomer R, Mata JG, Gascon P, Gasquet JA, Herdman M, Rodriguez CA, Sanchez J, Valentin V (2009) Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: item generation and item reduction. Value Health 12:130–138PubMedCrossRef
31.
Baro E, Herdman M, Gasquet J, Sánchez J (2004) Instruments to measure patient-reported outcomes and perceptions of cancer-related fatigue: a review of the literature. Value Health 7:PCN32CrossRef
32.
Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412–3425PubMed
33.
Munch TN, Zhang T, Willey J, Palmer JL, Bruera E (2005) The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med 8:1144–1149PubMedCrossRef
34.
Ludwig H (2002) Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 29:45–54PubMed
35.
Osterborg A (1998) Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 15(Suppl 1):S47–S49PubMed
36.
Aapro MS, Cella D, Zagari M (2002) Age, anemia, and fatigue. Semin Oncol 29:55–59PubMed
37.
Haghighat S, Akbari ME, Holakouei K, Rahimi A, Montazeri A (2003) Factors predicting fatigue in breast cancer patients. Support Care Cancer 11:533–538PubMedCrossRef
38.
Shun SC, Lai YH, Jing TT, Jeng C, Lee FY, Hu LS, Cheng SY (2005) Fatigue patterns and correlates in male liver cancer patients receiving transcatheter hepatic arterial chemoembolization. Support Care Cancer 13:311–317PubMedCrossRef
39.
40.
Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ (2007) Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 26:660–667PubMedCrossRef
41.
Luctkar-Flude MF, Groll DL, Tranmer JE, Woodend K (2007) Fatigue and physical activity in older adults with cancer: a systematic review of the literature. Cancer Nurs 30:E35–E45PubMedCrossRef
42.
Revicki DA, Stull D, Vernon M, Rader M, Tomita D, Viswanathan HN (2012) Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials. Qual Life Res 21:311–321PubMedCrossRef
43.
44.
Esquerdo G, Llorca C, Cervera JM, Orts D, Juarez A, Carrato A (2011) Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level Clin Transl Oncol 13:341–347
45.
46.
De Waele S, Van Belle S (2010) Cancer-related fatigue. Acta Clin Belg 65:378–385PubMed
47.
Seyidova-Khoshknabi D, Davis MP, Walsh D (2011) Review article: a systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care 28:119–129PubMedCrossRef
48.
Agasi-Idenburg C, Velthuis M, Wittink H (2010) Quality criteria and user-friendliness in self-reported questionnaires on cancer-related fatigue: a review. J Clin Epidemiol 63:705–711PubMedCrossRef
Metadata
Title
Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study
Publication date
01-11-2013
Published in
Supportive Care in Cancer / Issue 11/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1862-z

Other articles of this Issue 11/2013

Supportive Care in Cancer 11/2013 Go to the issue

Review Article

Emerging evidence on the pathobiology of mucositis

Erratum

Erratum to: Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor

Original Article

Psychometric properties of the Chinese version of Sexual Function after Gynecologic Illness Scale (SFAGIS)

Original Article

Surprising results regarding MASCC members' beliefs about spiritual care

Original Article

Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion

Original Article

Couple distress after localised prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits